Staphylococcus aureus relies on quorum sensing to exert virulence to establish and maintain infection. Prior research demonstrated the potent quorum sensing inhibition effects of "430D-F5", a refined extract derived from the fruits of Schinus terebinthifolia, a medicinal plant used for the traditional treatment of skin and soft tissue infections. We report the isolation and identification of three compounds from 430D-F5 that reduce virulence and abate dermonecrosis: 3-oxo-olean-12-en-28-oic acid (1), 3-oxotirucalla-7,24Z-dien-26-oic acid (2) and 3α-hydroxytirucalla-7,24 Z-dien-27-oic acid (3). Each compound inhibits all S. aureus accessory gene regulator (agr) alleles (IC 50 2-70 μM). Dosedependent responses were also observed in agr-regulated reporters for leucocidin A (lukA, IC 50 0.4-25 μM) and glycerol ester hydrolase or lipase (gehB, IC 50 1.5-25 μM). Surprisingly, dose-dependent activity against the nuclease reporter (nuc), which is under the control of the sae two-component system, was also observed (IC 50 0.4-12.5 μM). Compounds 1-3 exhibited little to no effect on the agrindependent mgrA P2 reporter (a constitutive promoter from the mgrA two-component system) and the esxA reporter (under control of mgrA). Compounds 1-3 inhibited δ-toxin production in vitro and reduced dermonecrosis in a murine in vivo model. This is the first report of triterpenoid acids with potent antivirulence effects against S. aureus. Staphylococcus aureus has long been recognized as a significant cause of both community-acquired (CA) and healthcare associated (HA) infections, such as endocarditis, septic arthritis, osteomyelitis, and necrotizing pneumonia 1. In the past decade, an increasing number of infections by methicillin-resistant S. aureus (MRSA) have been documented and estimates in the United States suggest that MRSA causes between 11,000-18,000 deaths and 80,000 invasive infections annually 2,3. Furthermore, a single clone of CA-MRSA (USA300) has emerged as the most common cause of all skin and soft tissue infections in the United States and continues to pose a serious public health threat in community and healthcare settings 4,5. With the last novel class of antibiotics to be brought to market being discovered in the 1980s, new strategies are necessary to respond to the widespread development of antibiotic resistant infections 6. Some promising future approaches include promoting infection prevention to reduce the need for antibiotics, encouraging investment in antimicrobial agents with new regulatory policies and economic models, slowing the spread of resistance in order to preserve the useful lives of available antibiotics, and developing novel therapeutics that modulate host-microbe interactions without placing direct selective pressures known to drive resistance resistance 7. S. aureus antibiotic resistance can be due to various extrinsic, or acquired, mechanisms such as enzymatic drug modification, mutated drug targets, enhanced efflux pump expression, and altered membrane permeability 8. Additionally, intrinsic mec...